心血管

订阅

MedSci主页 / 所有栏目 / 心血管

AHA 2013：脂蛋白(a)为剩余心血管风险的决定因素

2013-11-27 高晓方 译 医学论坛网

脂蛋白a剩余心血管风险决定因素
关注

于AHA 2013科学年会公布的美国一项研究表明，在接受有效他汀类治疗的患者中，脂蛋白(a)[ Lp(a)]为剩余心血管风险的显著决定因素。论文11月17日在线发表于《循环》（Circulation）。【原文下载】 Lp(a)是一种在很大程度上独立于已知危险因素的LDL样颗粒，但目前尚不清楚在有效他汀类治疗后LDL-胆固醇较低的情况下Lp(a)是否为剩余风险的决定因素。此项研究从JUP

于AHA 2013科学年会公布的美国一项研究表明，在接受有效他汀类治疗的患者中，脂蛋白(a)[ Lp(a)]为剩余心血管风险的显著决定因素。论文11月17日在线发表于《循环》（Circulation）。【原文下载】

Lp(a)是一种在很大程度上独立于已知危险因素的LDL样颗粒，但目前尚不清楚在有效他汀类治疗后LDL-胆固醇较低的情况下Lp(a)是否为剩余风险的决定因素。此项研究从JUPITER试验中纳入9612例受试者，并在其随机接受瑞舒伐他汀20 mg/d或安慰剂前后测定了基线和治疗时Lp(a)浓度。

结果显示，Lp(a)浓度在黑人中最高，其次亚裔人、西班牙裔人和白人。尽管瑞舒伐他汀和安慰剂组的Lp(a)中位变化为零，但瑞舒伐他汀使总体Lp(a)分布出现微小但具有统计学意义的积极变化。基线Lp(a)浓度与事件性心血管疾病相关（校正危险比HR 1.18）。他汀类治疗时Lp(a)浓度与心血管疾病剩余风险相关，并且独立于LDL-胆固醇和其他因素。在基线Lp(a)浓度≥和<均值的受试者中，瑞舒伐他汀均使心血管疾病出现显著减少。当将非白人受试者纳入其中也获得相类似的结果。


原文出处：

Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S.Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis from the JUPITER Trial.Circulation. 2013 Nov 17. 【原文下载】

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2082338, encodeId=7d61208233822, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Mar 23 13:29:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671002, encodeId=294516e100245, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Tue Apr 15 22:29:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267195, encodeId=d385126e195aa, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 29 01:29:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424634, encodeId=08f5142463490, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Nov 29 01:29:00 CST 2013, time=2013-11-29, status=1, ipAttribution=)]
    2014-03-23 ms5353107019656438

    #血管风险#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2082338, encodeId=7d61208233822, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Mar 23 13:29:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671002, encodeId=294516e100245, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Tue Apr 15 22:29:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267195, encodeId=d385126e195aa, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 29 01:29:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424634, encodeId=08f5142463490, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Nov 29 01:29:00 CST 2013, time=2013-11-29, status=1, ipAttribution=)]
    2014-04-15 wushaoling

    #决定因素#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2082338, encodeId=7d61208233822, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Mar 23 13:29:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671002, encodeId=294516e100245, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Tue Apr 15 22:29:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267195, encodeId=d385126e195aa, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 29 01:29:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424634, encodeId=08f5142463490, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Nov 29 01:29:00 CST 2013, time=2013-11-29, status=1, ipAttribution=)]
    2013-11-29 zhaohui6731

    #AHA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2082338, encodeId=7d61208233822, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sun Mar 23 13:29:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671002, encodeId=294516e100245, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Tue Apr 15 22:29:00 CST 2014, time=2014-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267195, encodeId=d385126e195aa, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 29 01:29:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424634, encodeId=08f5142463490, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Nov 29 01:29:00 CST 2013, time=2013-11-29, status=1, ipAttribution=)]
    2013-11-29 juliusluan79

    #脂蛋白#

    0